Sage Therapeutics to Present at J.P. Morgan Healthcare Conference on Tuesday, January 10, 2017
January 03 2017 - 4:10PM
Business Wire
Sage Therapeutics (NASDAQ: SAGE), a clinical-stage
biopharmaceutical company developing novel medicines to treat
life-altering central nervous system (CNS) disorders, today
announced that the company is scheduled to present at the J.P.
Morgan 2017 Healthcare Conference in San Francisco on Tuesday,
January 10, 2017 at 9:30 a.m. PT (12:30 p.m. ET).
A live webcast of the presentation can be accessed on the
investor page of Sage's website at investor.sagerx.com. A
replay of the webcast will also be archived for up to 30 days on
Sage's website following the conference.
About Sage Therapeutics
Sage Therapeutics is a clinical-stage biopharmaceutical
company committed to developing novel medicines to transform the
lives of patients with life-altering central nervous system (CNS)
disorders. Sage has a portfolio of novel product candidates
targeting critical CNS receptor systems, GABA and NMDA. Sage's lead
program, SAGE-547, is in Phase 3 clinical development for
super-refractory status epilepticus, a rare and severe seizure
disorder, and for postpartum depression. Sage is developing its
next generation modulators, including SAGE-217 and SAGE-718, with a
focus on acute and chronic CNS disorders. For more information,
please visit www.sagerx.com.
View source
version on businesswire.com: http://www.businesswire.com/news/home/20170103006148/en/
Investor Contact:Sage TherapeuticsPaul Cox,
617-299-8377paul.cox@sagerx.comorMedia Contact:Suda
Communications LLCMaureen L. Suda,
585-387-9248maureen.suda@sagerx.com
Sage Therapeutics (NASDAQ:SAGE)
Historical Stock Chart
From Apr 2024 to May 2024
Sage Therapeutics (NASDAQ:SAGE)
Historical Stock Chart
From May 2023 to May 2024